Rationale and Design of the Canadian Lipoprotein(a) Registry Authors: Adam I Kramer, Husam Abdel-Qadir, Beth L Abramson, Alexis Baass, Jean Bergeron, Apoorva Bollu, Lubomira Cermakova, Patrick Couture, Christopher B Fordyce, Milan Gupta, Robert A Hegele, GB John Mancini, Ruth McPherson, Nathaniel Moulson, Glen J Pearson, Thomas Roston, Isabelle Ruel, Tara Sedlak, Mark H Sherman, George Thanassoulis, Jacob A Udell, Subodh Verma, Darryl Wan, Iulia Iatan, Liam R Brunham Published: 2026 ABSTRACT AbstractLipoprotein(a) [Lp(a)] is an independent, heritable risk factor for atherosclerotic cardiovascular disease. Guidelines recommend Lp(a) testing once in a lifetime and recognize it as a risk-enhancing factor. However, management of elevated Lp(a) in real-world clinical practice is not well described. Here we describe the rationale, design, and preliminary baseline characteristics of the Canadian Lp(a) Registry, a prospective, longitudinal observational study of patients with Lp(a) ≥ 100 nmol/L (≥ 50 mg/dL). Patient demographics, cardiovascular risk factors, laboratory results, and clinical outcomes are collected at baseline and at annual follow-up. The primary objective is to evaluate the clinical management and outcomes of patients with elevated Lp(a). From April 2024 to April 2025, 127 patients (mean age 57.5 ± 12.7 years, 48.8% female) were enrolled with a median Lp(a) level of 225 nmol/L (interquartile range 186-346 nmol/L), and 51.2% had multiple Lp(a) levels obtained. The most recent mean low-density lipoprotein cholesterol (LDL-C) was 2.49 ± 1.74 mmol/L. At the time of registry entry, 104 (81.9%) patients were receiving lipid-lowering therapies, including statins (74.8%), ezetimibe (48.0%), and proprotein convertase subtilisin/kexin type 9 inhibitors (27.6%), whereas 18.1% were not taking prescription lipid-lowering therapy. There were 66 (52.0%) patients with an LDL-C < 2.0 mmol/L. The Canadian Lp(a) Registry is an ongoing prospective, observational study designed to evaluate the clinical management, cardiovascular risk profile, and outcomes for patients with elevated Lp(a). It is expected to improve our understanding of how elevated Lp(a) is managed in contemporary clinical practice and to identify opportunities to improve care.Keywords: atherosclerotic cardiovascular disease, lipoprotein(a), low-density lipoprotein cholesterol, registry Lipoprotein(a) [Lp(a)] is a particle that is structurally similar to low-density lipoprotein (LDL-C), with a key distinction due to the addition of apolipoprotein(a) [Apo(a)] covalently linked through a disulfide bond. Lp(a) is an independent genetic risk factor for adverse cardiovascular outcomes, including atherosclerotic cardiovascular disease (ASCVD), calcific aortic stenosis, and ischemic stroke.1,2 The relative risk increase for myocardial infarction (MI) associated with elevated Lp(a) can range from 1.5- to 4-fold depending on the degree of Lp(a) elevation, with a log-linear relationship.3, 4, 5 Levels of Lp(a) are predominantly determined by genetic variation at the LPA gene locus on chromosome 6, and levels of Lp(a) are relatively stable over an individual’s lifetime. Elevated Lp(a) is often defined as a level above the 80th percentile of the population, which has been defined in many guidelines as a level ≥ 100 nmol/L (equating to roughly 50 mg/dL).6 However, Lp(a) concentrations vary across ethnic groups, with individuals of African ancestry having higher median Lp(a), followed by individuals of South Asian descent.6,7 Lp(a) levels are also 12% higher on average in females compared with males.7 The risk of coronary artery disease, MI, aortic stenosis, and stroke increases at Lp(a) levels > 100 nmol/L.3,8 There are currently no pharmacologic therapies approved for reducing Lp(a) levels, but several are under investigation. In a phase 2 clinical trial, the antisense oligonucleotide pelacarsen produced significant, dose-dependent reductions in Lp(a) levels, ranging from 35% to 80%, in patients with stable ASCVD.9 The short interfering RNA olpasiran reduced Lp(a) by up to 97% in phase 2 trials.10,11 Both pelacarsen and olpasiran have demonstrated excellent safety profiles and are currently being evaluated in phase 3 trials to determine whether lowering elevated Lp(a) levels translates into reduced ASCVD risk.12,13 Several other prospective Lp(a)-lowering therapies are also under investigation in early-stage clinical trials.14, 15, 16 Evaluating the efficacy and risk reduction properties of these therapeutics, and appropriately using them for patients, will require a better understanding of the populations that are most impacted by elevated Lp(a) and of their coexisting traditional ASCVD risk factors. Rationale for the Canadian Lp(a) Registry Multiple national and international guidelines recommend measuring the Lp(a) level once in an individual’s lifetime, including the Canadian Cardiovascular Society (CCS), European Society of Cardiology/European Atherosclerosis Society (ESC/EAS), the National Lipid Association (NLA), and the American College of Cardiology/American Heart Association (ACC/AHA).17, 18, 19, 20 The 2026 ACC/AHA guideline on cholesterol management considers elevated Lp(a) a risk-enhancing factor at levels ≥ 125 nmol/L that can indicate a need to escalate lipid-lowering therapy. The guideline also suggests that secondary prevention patients with elevated Lp(a) may preferentially benefit from addition of a PCSK9 inhibitor (PCSK9i) when treatment goals are not being met on maximally tolerated statin therapy.20 The CCS recommends using an Lp(a) level > 100 nmol/L as a risk-enhancing factor for patients being managed for primary prevention. In the case of secondary prevention, the CCS guideline suggests using elevated Lp(a) level to identify patients who will derive greatest benefit from PCSK9i as a means of intensifying lipid-lowering therapy (LLT), which may be particularly relevant after acute coronary syndrome.18 In contrast to the CCS recommendation, the Patients Experience Evidence Research (PEER) guideline, designed for family physicians in Canada, recommends against Lp(a) testing.21 These conflicting recommendations underscore the need for real-world data regarding the clinical impact of measuring Lp(a). Data regarding Lp(a) measurement and implementation are scarce, whereas the limited data that are available suggest it is used relatively infrequently.22,23 Various factors could account for its underuse, including lack of familiarity with Lp(a) among practitioners, inconsistent guideline recommendations, lack of approved Lp(a)-lowering therapies, and lack of clinical trial data demonstrating improved outcomes associated with its measurement.18,21,24 Clinical registries are tools to collect observational real-world data regarding populations or topics of interest. Registries are particularly powerful for conditions for which data are limited, either due to low prevalence or low rates of diagnosis.25 The latter is true for Lp(a) and is related to underuse of testing, despite it being an insured test in most of Canada.18,26 The prevalence of Lp(a) testing in Canada is not precisely known. In Alberta, Canada, 29,229 Alberta residents had Lp(a) levels tested between January 2015 and March 2023, which represents < 1% of the province’s population.23 In a large health system in California, the overall prevalence of testing was similarly extremely low at 0.3%.27 Importantly, Lp(a) meets most of the established criteria for an acceptable population screening test.28 The creation of a national Lp(a) registry would serve a number of beneficial purposes. These include identifying areas of health care inequity and improving understanding of disease prevalence, associated comorbidities, outcomes, and current management practices. By extension, this information can identify gaps in the implementation of clinical practice guidelines and potentially help direct health care resources. A recent retrospective cohort study of patients who underwent Lp(a) testing in Alberta, Canada, showed that health care resource use costs among patients with established ASCVD tended to have a linearly increasing relationship with Lp(a) levels.23 Finally, registry data may help enable future research with the goal of improving health outcomes and providing targeted therapies, as well as identifying those who are likely to obtain the greatest benefit from these therapies.25 Aims of the Canadian Lp(a) Registry In this study we describe the design of the Canadian Lp(a) Registry to address gaps in knowledge relating to the clinical use of Lp(a) levels in risk stratification and facilitating guideline-directed treatment decisions. We also provide preliminary baseline characteristics of the Canadian Lp(a) Registry, following its launch in April 2024. The objectives of the registry are to: 1) establish a registry of patients with elevated Lp(a), identified through routine care, as currently defined and supported by national guidelines for assessment and management of dyslipidemia; 2) characterize the profile of patients with elevated Lp(a) in terms of traditional cardiovascular risk factors, including ethnic and sex differences; 3) quantify the degree to which coexisting, traditional modifiable risk factors, including other atherogenic lipids, are being treated; 4) examine the role of genetic background on cardiovascular outcomes in patients with elevated Lp(a); and 5) evaluate the cardiovascular outcomes of these patients and understand their health care use. Methods Inclusion criteria and enrollment The Canadian Lp(a) Registry is hosted by the University of British Columbia Centre for Heart Lung Innovation. Enrollment will occur through a network of lipid, cardiology, general internal medicine, and endocrinology clinics around the country. Efforts will be made to extend enrollment to include primary care practices, if feasible. Early recruitment is expected to be enriched for patients seen in specialty clinics; broader recruitment, including nonspeciality settings, will be pursued as additional sites operationalize. Patients ≥ 18 years of age, with or without a prior history of ASCVD, will be eligible for inclusion if they have an Lp(a) ≥ 100 nmol/L (or ≥ 50 mg/dL) and consent to participate. This threshold was selected based on evidence that the risk of ASCVD rises with increasing Lp(a) levels beyond this value and to remain consistent with CCS guidelines.4,7,18 Most clinical laboratories in Canada use molar assays. However, Lp(a) assays are not fully standardized across laboratories, and values obtained from different laboratories may not be directly comparable. Historical mass-based values will also be accepted. Although direct conversion between mass- and molar-based assay units is generally not recommended, inclusion of historical mass-based values allows broader real-world capture of patients currently managed in Canadian practice. As such, results reported in mg/dL will be converted to nmol/L using the formula: 2.18 × [mg/dL] − 3.83.29 In cases where multiple Lp(a) levels are available, all measurements will be captured and the result reported in nmol/L or the highest level used for analysis. Clinical management decisions will be determined by the treating physicians, and patients will be managed according to standard of care. Cascade screening will be supported by providing participants with educational material about the inherited nature of Lp(a) and the importance of their relatives being tested. Patients will be excluded if they are unable or unwilling to provide written, informed consent, or if they are unable to attend follow-up clinic visits. Patients will also be excluded if they have a known secondary cause of elevated Lp(a), specifically nephrotic syndrome and/or untreated hypothyroidism (defined as a level of thyroid-stimulating hormone > 10 mIU/L). Data collection The Canadian Lp(a) Registry has a prospective, longitudinal observational study design. Data will be collected from the patients’ medical records, supplemented by data obtained directly from the patient through questionnaires (Supplemental Appendix S1: Methods). All data will be recorded in a secured REDCap database using a standardized case report form. The REDCap database will allow for longitudinal data collection with annual follow-ups to reassess the status of cardiovascular risk factors, occurrence of major adverse cardiovascular events (MACEs), and other changes to health. In addition, updated physical examination, laboratory, and imaging information will be included (Supplemental Fig. S1). If baseline untreated LDL-C data are unavailable, imputed LDL-C will be used (https://www.circl.ubc.ca/english/web_ldl2.html).30 As part of a future phase of the registry all patients will be invited to participate in an optional genetics substudy, with the data to be used for genome-wide genotyping and determination of genome-wide polygenic risk scores, as well as other genomic biomarkers of interest.31 Endpoints and analyses The primary endpoints include: 1) the occurrence of MACEs and aortic stenosis events; and 2) attainment of guideline-directed lipid targets as recommended by the CCS guidelines for the management of dyslipidemia, including treatment patterns of the registry population at baseline and during follow-up, which also includes the proportion of patients on LLT.18 Target attainment will be assessed according to guideline-recommended thresholds and stratified by ASCVD status, with additional analyses by familial hypercholesterolemia (FH) status and Framingham Risk Score, as appropriate. MACEs will be identified based on chart review and patient follow-up, and will be defined as MI, arterial revascularization, hospitalization for unstable angina, stroke, cardiovascular mortality, and all-cause mortality. Peripheral vascular events will be captured and reported separately. Aortic stenosis events will be identified as new or progression of aortic stenosis or aortic valve replacement. Classification of aortic stenosis severity (mild, moderate, or severe) will be based on standard definitions for aortic valve area, peak velocity, and mean gradient, and will be determined based on clinical data and echocardiogram results, if available.32 Follow-up data for assessing endpoints will be obtained annually. Secondary analyses include: 1) cardiovascular risk factor profiles, including traditional risk factors; 2) lipid levels and treatment patterns at baseline and follow-up; 3) geographic distribution of individuals with elevated Lp(a); 4) sex-related differences in treatment patterns and outcomes; and 5) incidence of MACEs in individuals stratified by polygenic risk score. Objectives and associated endpoints are summarized in Table 1. A general overview of the proposed study workflow is outlined in Figure 1. Table 1Objectives and corresponding endpoints of the Canadian Lp(a) RegistryObjectiveEndpoint1. Establish a registry of patients with elevated Lp(a)•Establishment of the Canadian Lp(a) Registry2. Characterize the profile of patients with elevated Lp(a)•Cardiovascular risk profile, including traditional modifiable risk factors and family history, of registry population•Geographic distribution of patients•Sex-related and ethnic differences in risk factor profile3. Quantify the degree to which traditional modifiable risk factors are being treated•Proportion of patients on LLT and meeting guideline-directed targets•Sex-related differences in treatment patterns4. Examine the role of genetic background on cardiovascular outcomes•Incidence of MACEs stratified by polygenic risk score5. Evaluate cardiovascular outcomes and health care use of patients with elevated Lp(a)•Incidence of MACEs•Sex-related differences in incidence of MACEsLLT, lipid-lowering therapy; Lp(a), lipoprotein(a); MACE, major adverse cardiovascular event; NA, not applicable. Objectives and corresponding endpoints of the Canadian Lp(a) Registry •Establishment of the Canadian Lp(a) Registry Establishment of the Canadian Lp(a) Registry •Cardiovascular risk profile, including traditional modifiable risk factors and family history, of registry population Cardiovascular risk profile, including traditional modifiable risk factors and family history, of registry population •Geographic distribution of patients Geographic distribution of patients •Sex-related and ethnic differences in risk factor profile Sex-related and ethnic differences in risk factor profile •Proportion of patients on LLT and meeting guideline-directed targets Proportion of patients on LLT and meeting guideline-directed targets •Sex-related differences in treatment patterns Sex-related differences in treatment patterns •Incidence of MACEs stratified by polygenic risk score Incidence of MACEs stratified by polygenic risk score •Incidence of MACEs Incidence of MACEs •Sex-related differences in incidence of MACEs Sex-related differences in incidence of MACEs LLT, lipid-lowering therapy; Lp(a), lipoprotein(a); MACE, major adverse cardiovascular event; NA, not applicable. Study overview and workflow. Patients will be eligible for inclusion if they have a current or historical Lp(a) value of > 100 nmol/L or > 50 mg/dL. Information will be collected from patients’ medical records and entered into the study database. Treatment will be performed according to standard of care. Patients will be followed longitudinally coinciding with clinically indicated visits. Lp(a), lipoprotein(a). Statistical analyses The registry is expected to operate for a minimum duration of 5 years or until a minimum of 1000 registrants have completed both the baseline and 1-year follow-up assessments, whichever occurs first. Interim analysis at that time will determine the appropriateness of continuing the registry. Descriptive statistics will be used to summarize the registry population characteristics at baseline and follow-up. Intergroup comparisons of continuous variables will be assessed using the Welch t test. Changes between baseline and follow-up data at 1 year will be compared via paired t tests for continuous variables or by McNemar test for categorical variables. Analyses will be also be performed according to Lp(a) level using various cutoffs, including ≥ 100 nmol/L, ≥ 250 nmol/L, and ≥400 nmol/L. Factors associated with the initiation of LLTs will be evaluated using multivariable logistic regression models, including a prespecified set of clinically relevant covariates, selected a priori [eg, age, sex, Lp(a) level, FH, baseline LDL-C, diabetes, hypertension, and prior ASCVD]. In addition, exploratory analyses of other clinical and demographic variables will be performed by adding them individually to the core model. Key analyses will be stratified by FH whenever applicable. Results will be reported as effect estimates with corresponding confidence intervals. A two-sided P value < 0.05 will be considered statistically significant, whereas P values between 0.05 and 0.1 will be considered hypothesis-generating. Rates of MACEs and associated predictors will be assessed using Cox regression models. Ethics Informed consent will be obtained prior to registry enrollment. The study has been approved by the research ethics boards of the University of British Columbia and all participating sites. The Canadian Lp(a) Registry will be registered on www.clinicaltrials.gov. Results Baseline characteristics of the first 127 patients included in the Canadian Lp(a) Registry are summarized in Table 2. The mean age of participants was 58 years, and 48.8% of participants are women. The median Lp(a) level was 225 nmol/L (interquartile range [IQR] 186-346 nmol/L), with a median 201 nmol/L (IQR 176-281 nmol/L) in men and 301 nmol/L (IQR 206-381 nmol/L) in women (P < 0.001). The mean Lp(a) level was 263 ± 108 nmol/L and was significantly higher in women (296 ± 106 nmol/L) than in men (233 ± 101 nmol/L) (P < 0.01). Multiple Lp(a) levels were performed for 65 (51.2%) participants. Established ASCVD was common, with 18.1% having a prior MI and 33.1% having a history of coronary revascularization. A history of stroke or transient ischemic attack was present in 3.1% of patients, and 3.9% had a history of severe aortic stenosis. Peripheral vascular events had occurred in 2.4% of patients. Table 2Baseline characteristics of Canadian Lp(a) Registry participantsCharacteristicsDemographics Patients enrolled, n127 Men, n (%)65 (51.2%) Age, years (mean ± SD)57.5 ± 12.7Clinical risk factors Probable or definite FH, n (%)43 (33.9%) Current or previous smoking, n (%)46 (36.2%) Hypertension, n (%)41 (32.3%) Diabetes, n (%)14 (11.0%)Cardiovascular and valvular disease Myocardial infarction, n (%)23 (18.1%) Unstable angina, n (%)26 (20.5%) Coronary revascularization, n (%)42 (33.1%) Stroke/transient ischemic attack, n (%)4 (3.1%) Severe aortic stenosis, n (%)5 (3.9%) Peripheral vascular events, n (%)3 (2.4%)Baseline lipid profile Lipoprotein(a), nmol/L (median [IQR])225 [186-346] Lipoprotein(a), nmol/L (mean ± SD)263 ± 108 Patients with > 1 Lp(a) test, n (%)65 (51.2%) LDL-C, mmol/L (mean ± SD)2.49 ± 1.74 Non–HDL-C, mmol/L (mean ± SD)3.00 ± 1.83 HDL-C, mmol/L (mean ± SD)1.42 ± 0.44 Apolipoprotein B, g/L (mean ± SD)0.82 ± 0.38 Triglycerides, mmol/L (mean ± SD)1.06 ± 0.58 LDL-C < 2.0 mmol/L, n (%)66 (52.0%) LDL-C < 1.8 mmol/L, n (%)55 (43.3%)Lipid-lowering therapy Statin, n (%)95 (74.8%) Ezetimibe, n (%)61 (48.0%) PCSK9i, n (%)35 (27.6%) Other lipid-lowering therapy, n (%)2 (1.6%) Multiple lipid-lowering therapies, n (%)67 (52.8%) No prescribed lipid-lowering therapy, n (%)23 (18.1%)FH, familial hypercholesterolemia; HDL-C, high-density lipoprotein cholesterol; IQR, interquartile range; LDL-C, low-density lipoprotein cholesterol; PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor; SD, standard deviation. Baseline characteristics of Canadian Lp(a) Registry participants FH, familial hypercholesterolemia; HDL-C, high-density lipoprotein cholesterol; IQR, interquartile range; LDL-C, low-density lipoprotein cholesterol; PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor; SD, standard deviation. The mean LDL-C level among the participants at the time of entry into the registry was 2.49 ± 1.74 mmol/L. In comparison, the mean baseline LDL-C level, if known, or imputed baseline LDL-C level was 5.27 ± 1.93 mmol/L, and 33.9% of participants met criteria for probable or definite FH. Statin use was prevalent (74.8%) and 52.8% of participants were prescribed more than one LLT. However, 23 (18.1%) patients were not prescribed any LLT at baseline. At the time of entry into the registry, 66 (52.0%) patients had an LDL-C < 2.0 mmol/L (or, if LDL-C was not available, ApoB < 0.8 g/L or non–HDL-C < 2.6 mmol/L), representing the CCS thresholds for intensifying LLT in the setting of primary prevention.18 In comparison, 55 (43.3%) patients were below the secondary prevention treatment thresholds outlined by the CCS, which suggest intensification of therapy if LDL-C ≥ 1.8 mmol/L (or, if LDL-C was not available, ApoB ≥ 0.7 g/L or non–HDL-C ≥ 2.4 mmol/L).18 Other common modifiable risk factors include current or previous smoking (36.2%), hypertension (32.3%), and diabetes (11.0%). Discussion In this study we have described the design, rationale, and preliminary baseline results of the Canadian Lp(a) Registry. The preliminary characteristics of the first 127 patients in the registry provide early insights into the implementation of clinical practice guidelines. It is notable that 18.1% were not on any LLT and only 52.0% achieved an LDL-C level below the CCS primary prevention treatment threshold.18 The relatively low proportion of patients achieving primary prevention targets may reflect, in part, the high proportion of registry patients with probable or definite FH and, therefore, a high pretreatment LDL-C. It could also reflect a lack of familiarity with Lp(a) among practitioners, as approximately half of patients had repeated Lp(a) tests. The results of this registry could eventually be used for knowledge translation to increase awareness of Lp(a) among patients and health care providers, and by accelerating the uptake of evidence-based interventions that reduce cardiovascular risk in this population. There are many potential benefits of creating a national registry of patients with elevated Lp(a).25,33 Canada is a diverse country, spanning a large geographic area and including individuals from many ethnic backgrounds. Use of a national registry could help determine differences in disease burden, cardiovascular outcomes, and clinical management among different groups, and identifying gaps or regional disparities in care. The implementation of clinical practice guidelines can be assessed by measuring the optimization of cardiovascular risk factors over time on a national scale. By improving understanding of current clinical practices, the use of a national Lp(a) registry can identify gaps in care and opportunities for education. Finally, from a research standpoint, the standardized data collected as part of a registry can be immensely helpful for enabling additional research, as well as identifying patients who may benefit from novel therapeutic agents, particularly those with extreme elevations of Lp(a).25 This model of registry has been successfully implemented in Canada for the FH Canada Registry, which was originally established in British Columbia prior to expanding across the country through the addition of peripheral sites that enter data directly into a centralized database.34,35 One of the benefits of the FH Canada Registry is the ability to identify individuals for whom cascade screening of relatives would be beneficial.35 Given that Lp(a) levels are predominantly genetically determined, the Canadian Lp(a) Registry may provide similar opportunities in the future to engage in genetic screening among interested patients. Lp(a) levels have been included in several registries as a variable of interest, but there are few publications detailing registries designed explicitly for Lp(a) (Table 3).36, 37, 38, 39, 40, 41, 42 The Mass General Brigham Lp(a) Registry represents a large cohort of patients with Lp(a) measurements followed longitudinally for up to 1 year after Lp(a) testing.43 Data from that registry demonstrated that, among those without prior ASCVD, Lp(a) levels in the 90th or higher percentile group had almost double the risk. When isolated to a first incident MI, the risk was more than 3-fold higher in this group.44 Elevated Lp(a) was associated with an increased risk of first acute MI irrespective of any other modifiable risk factors. In addition, the risk associated with elevated Lp(a) had the equivalent risk of 2 modifiable risk factors, such as hypertension, diabetes, dyslipidemia, and smoking.45 The risk of MI attributable to elevated Lp(a) appears to be similar in women and men.46 The recently published United States Family Heart Database analyzed over 270,000 individuals with ASCVD and measured Lp(a) levels to provide valuable real-world data, although it is retrospective and not designed for longitudinal follow-up or participant re-engagement.47 Initial results of another Lp(a) registry, the Polish Mother’s Memorial Hospital Research Institute (PMMHRI), were published recently for the second largest hospital in Poland.48 This single-centre registry enrolls all consecutive patients seen at their cardiology, diabetes, and metabolic clinics who have had a Lp(a) measurement as per the Polish guidelines. Among the initial 511 patients, 27.8% were found to have elevated Lp(a) > 30 mg/dL and 19.8% had levels > 50 mg/dL.48 A second single-centre Polish registry, the Zabrze-Lipoprotein(a) [Zabrze-Lip(a)] Registry, has been established focussing on patients considered very high risk of ASCVD based on the ESC/EAS 2019 definition. Based on initial data of 2001 patients, 27% had a Lp(a) level > 30 mg/dL. That registry is intended to be prospective, with different phases of follow-up data to be collected regarding cardiovascular outcomes at 12, 24, 36, and 48 months.49 Also in Europe, the MEDIAN Lp(a) Registry is a multicentre registry with data from 10 cardiac rehabilitation facilities in Germany.50 It included several cohorts of patients who underwent aortic or coronary intervention with the aim of determining the frequency of Lp(a) testing and the prevalence of elevated Lp(a) levels in these groups. The frequency of Lp(a) testing was low, ranging from 0.19% to 4.96%. Elevated Lp(a) levels > 50 mg/dL or 125 nmol/L were common, with prevalence ranging from 24% to 36%.50 Table 3Comparison of previously published Lp(a) registries and the Canadian Lp(a) RegistryCanadian Lp(a) RegistryMass General Brigham Lp(a) RegistryPMMHRI Lp(a) RegistryZabrze-Lip(a) RegistryMEDIAN Lp(a) RegistryGeographic scopeNationalRegionalRegionalRegionalNationalSingle or multicentreMulticentreMulticentreSingle centreSingle centreMulticentreDesignProspective, longitudinalRetrospective, cohortProspective, longitudinalProspective, longitudinalProspective, cross-sectionalPopulation of focusElevated Lp(a)All individuals with a Lp(a) test resultMostly very high-risk primary preventionVery high ASCVD riskPrior coronary or aortic interventionMedian Lp(a) level225 nmol/L (105 mg/dL)35 mg/dL (72 nmol/L)NR7 mg/dL (16 nmol/L)19 mg/dL (38 nmol/L)Mean Lp(a) level263 nmol/L (122 mg/dL)NR30 mg/dL (62 nmol/L)14 mg/dL (27 nmol/L)41 mg/dL (86 nmol/L)Median or mean Lp(a) levels are provided in the units published for each registry, with converted units included in parentheses for reference.ASCVD, atherosclerotic cardiovascular disease; Lp(a), lipoprotein(a); NR, not reported. Comparison of previously published Lp(a) registries and the Canadian Lp(a) Registry Median or mean Lp(a) levels are provided in the units published for each registry, with converted units included in parentheses for reference. ASCVD, atherosclerotic cardiovascular disease; Lp(a), lipoprotein(a); NR, not reported. In contrast to these registries, which include patients at any level of Lp(a), the Canadian Lp(a) Registry is a prospective, longitudinal study of patients with elevated Lp(a) levels that will focus on assessing coexisting cardiovascular risk factors and their management. To our knowledge, this is the first registry dedicated to identifying patients with elevated Lp(a). As a result, the preliminary median and mean Lp(a) levels in the Canadian Lp(a) Registry are substantially higher than other existing Lp(a) registries (Table 3). As such, our registry will be uniquely enriched for individuals with very high Lp(a), enabling more granular study of this high-risk group. This will be particularly beneficial for identifying the patients best suited to benefit from targeted Lp(a)-lowering therapies if they become available in the future.12,13 In addition, it is the first prospectively designed longitudinal Lp(a) registry that is national in scope. Unlike other registries, the ability to recontact and actively engage with participants in the Canadian Lp(a) Registry will also support knowledge translation activities and accelerate the implementation of best practices. A Canadian framework for the screening, assessment, and management of elevated Lp(a) was recently published and offers expert recommendations about incorporating Lp(a) into clinical decision-making.51 The Canadian Lp(a) Registry also has several benefits relating to structural advantages in Canada. The health care system is publicly funded, which reduces some barriers to accessing medical care. This includes the provision of Lp(a) measurement in many provinces as a reimbursed service. The population is also diverse in its ethnic make-up, which lends to better generalizability of findings on a global scale. Limitations There are limitations to the registry design that warrant consideration. Data will be collected mainly from specialist clinics across Canada. However, Lp(a) measurement and access to medical care has regional variability. It is likely that patients from some regions, particularly more remote areas, will be underrepresented. First Nations populations may be affected in a similar manner, and this is an important area of unmet need.52 Codeveloped strategies will be implemented to improve recruitment of patients from these populations. Furthermore, early recruitment from speciality clinics may introduce a degree of ascertainment bias, as the sample population is likely to be enriched for a more severe clinical phenotype, including FH and established ASCVD. In particular, the preliminary results presented here reflect initial recruitment from specialty lipid clinics and should therefore be interpreted as reflective of early implementation rather than population-level prevalence. However, a broader recruitment and sampling of patients across additional clinical settings is expected as other clinical sites operationalize. Due to the high mean Lp(a) levels, it is possible that imputed LDL-C levels may overestimate true baseline LDL-C. Imputed LDL-C is only used when baseline levels are unavailable, which represents only a small proportion (< 15%) of cases. MACEs and valvular endpoints will be determined through chart review and scheduled follow-up at defined time points rather than centralized adjudication, which may result in under-ascertainment, particularly for nonfatal events. Conclusions The Canadian Lp(a) Registry is a prospective, longitudinal observational study designed to evaluate patients with elevated Lp(a) levels. The registry will provide valuable data pertaining to patient demographics, comorbidities, treatment patterns, and outcomes to evaluate the effects and clinical use of elevated Lp(a) levels (Central Illustration). Based on the preliminary baseline characteristics of the registry, nearly 1 in 5 patients with elevated Lp(a) are not on an LLT, and almost half are not achieving guideline-recommended lipid levels.18 The results of the Canadian Lp(a) Registry study will enable improved understanding of these patients’ ASCVD risk factors, their current management, and their cardiovascular outcomes, and will ultimately lead to improvements in their care and a reduction in the burden of ASCVD in this high-risk population. The design and preliminary baseline characteristics of the Canadian Lipoprotein(a) Registry, a national, prospective, longitudinal, observational study of patients with elevated Lp(a) ≥ 100 nmol/L (or ≥ 50 mg/dL). Preliminary baseline demographics and characteristics are presented for the first 127 patients enrolled in the registry. The registry will follow patients longitudinally to assess real-world treatment patterns and outcomes. Later phases of the registry will include an optional evaluation of genetic risk and will provide opportunities for knowledge translation and education. LDL-C, low-density lipoprotein; Lp(a), lipoprotein(a). Acknowledgements The authors thank the patients participating in the Canadian Lp(a) Registry. Ethics Statement The study was approved by the research ethics boards of the University of British Columbia and all participating sites. Patient Consent All patients provided written, informed consent. Funding Sources The Canadian Lp(a) Registry is supported by unrestricted grants or donations from Novartis, Amgen, and Eli Lilly. Disclosures Dr Bergeron reports receiving lecture fees from Amgen and HLS Therapeutics; grant support through participation in clinical trials sponsored by Amgen, Amryt, Arrowhead Pharmaceuticals, AstraZeneca, Eli Lilly, Ionis Pharmaceuticals, LIB Therapeutics, New Amsterdam Pharma, Novartis, Novo Nordisk, Regeneron Pharmaceuticals, Roche, Sanofi; and having served on advisory boards for Amgen, Medison, Novartis, Terratherapeutics, and Ultragenyx. Dr Gupta has served as a consultant for and received honoraria or speaking fees from Amgen, Sanofi, and Merck, and has collaborated with Amgen and Novartis on clinical trials. Dr Mancini has received honoraria and lecture fees and served as a consultant for Novartis, Amgen, and Eli Lilly, and has collaborated on clinical trials with Amgen and Novartis. Dr Moulson has received advisory fees from Novo Nordisk, Merck, HLS Therapeutics, and Amgen. The remaining authors have no conflicts of interest to disclose. Footnotes See page 1205 for disclosure information. To access the supplementary material accompanying this article, visit CJC Open at https://www.cjcopen.ca/ and at https://doi.org/10.1016/j.cjco.2026.06.003 Contributor Information Iulia Iatan, Email: Iulia.Iatan@mcgill.ca. Liam R. Brunham, Email: Liam.brunham@ubc.ca. Supplementary Material Supplementary Appendix S1 References Associated Data Supplementary Materials Supplementary Appendix S1